Search: onr:"swepub:oai:DiVA.org:uu-124604" >
Comparison of imati...
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia : a European LeukemiaNet Study
-
Baccarani, Michele (author)
-
Rosti, Gianantonio (author)
-
Castagnetti, Fausto (author)
-
show more...
-
Haznedaroglu, Ibrahim (author)
-
Porkka, Kimmo (author)
-
Abruzzese, Elisabetta (author)
-
Alimena, Giuliana (author)
-
Ehrencrona, Hans (author)
-
Hjorth-Hansen, Henrik (author)
-
Kairisto, Veli (author)
-
Levato, Luciano (author)
-
Martinelli, Giovanni (author)
-
Nagler, Arnon (author)
-
Lanng Nielsen, Johan (author)
-
Ozbek, Ugur (author)
-
Palandri, Francesca (author)
-
Palmieri, Fausto (author)
-
Pane, Fabrizio (author)
-
Rege-Cambrin, Giovanna (author)
-
Russo, Domenico (author)
-
Specchia, Giorgina (author)
-
Testoni, Nicoletta (author)
-
Weiss-Bjerrum, Ole (author)
-
Saglio, Giuseppe (author)
-
- Simonsson, Bengt (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2009
- 2009
- English.
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 113:19, s. 4497-4504
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the suggestion that better results could be achieved with a higher dose. To investigate whether the systematic use of a higher dose of IM could lead to better results, 216 patients with Ph(+) CML at high risk (HR) according to the Sokal index were randomly assigned to receive IM 800 mg or 400 mg daily, as front-line therapy, for at least 1 year. The CCgR rate at 1 year was 64% and 58% for the high-dose arm and for the standard-dose arm, respectively (P = .435). No differences were detectable in the CgR at 3 and 6 months, in the molecular response rate at any time, as well as in the rate of other events. Twenty-four (94%) of 25 patients who could tolerate the full 800-mg dose achieved a CCgR, and only 4 (23%) of 17 patients who could tolerate less than 350 mg achieved a CCgR. This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Baccarani, Miche ...
-
Rosti, Giananton ...
-
Castagnetti, Fau ...
-
Haznedaroglu, Ib ...
-
Porkka, Kimmo
-
Abruzzese, Elisa ...
-
show more...
-
Alimena, Giulian ...
-
Ehrencrona, Hans
-
Hjorth-Hansen, H ...
-
Kairisto, Veli
-
Levato, Luciano
-
Martinelli, Giov ...
-
Nagler, Arnon
-
Lanng Nielsen, J ...
-
Ozbek, Ugur
-
Palandri, France ...
-
Palmieri, Fausto
-
Pane, Fabrizio
-
Rege-Cambrin, Gi ...
-
Russo, Domenico
-
Specchia, Giorgi ...
-
Testoni, Nicolet ...
-
Weiss-Bjerrum, O ...
-
Saglio, Giuseppe
-
Simonsson, Bengt
-
show less...
- Articles in the publication
-
Blood
- By the university
-
Uppsala University